These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38842325)

  • 21. Oral miltefosine treatment in children with visceral leishmaniasis: a brief review.
    Palumbo E
    Braz J Infect Dis; 2008 Feb; 12(1):2-4. PubMed ID: 18553005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Miltefosine to treat leishmaniasis.
    Berman J
    Expert Opin Pharmacother; 2005 Jul; 6(8):1381-8. PubMed ID: 16013987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interspecies prediction of pharmacokinetics and tissue distribution of doxorubicin by physiologically-based pharmacokinetic modeling.
    Lee JB; Zhou S; Chiang M; Zang X; Kim TH; Kagan L
    Biopharm Drug Dispos; 2020 Apr; 41(4-5):192-205. PubMed ID: 32342986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Model-Based Approach To Assessing the Importance of Intracellular Binding Sites in Doxorubicin Disposition.
    Dubbelboer IR; Lilienberg E; Sjögren E; Lennernäs H
    Mol Pharm; 2017 Mar; 14(3):686-698. PubMed ID: 28182434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Physiologically based pharmacokinetic models of 2',3'-dideoxyinosine.
    Kang HJ; Wientjes MG; Au JL
    Pharm Res; 1997 Mar; 14(3):337-44. PubMed ID: 9098877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
    Zhang F; Tagen M; Throm S; Mallari J; Miller L; Guy RK; Dyer MA; Williams RT; Roussel MF; Nemeth K; Zhu F; Zhang J; Lu M; Panetta JC; Boulos N; Stewart CF
    Drug Metab Dispos; 2011 Jan; 39(1):15-21. PubMed ID: 20947617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimation of placental and lactational transfer and tissue distribution of atrazine and its main metabolites in rodent dams, fetuses, and neonates with physiologically based pharmacokinetic modeling.
    Lin Z; Fisher JW; Wang R; Ross MK; Filipov NM
    Toxicol Appl Pharmacol; 2013 Nov; 273(1):140-58. PubMed ID: 23958493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis.
    Castro MD; Gomez MA; Kip AE; Cossio A; Ortiz E; Navas A; Dorlo TP; Saravia NG
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma and Hepatic Concentrations of Chemicals after Virtual Oral Administrations Extrapolated Using Rat Plasma Data and Simple Physiologically Based Pharmacokinetic Models.
    Kamiya Y; Otsuka S; Miura T; Takaku H; Yamada R; Nakazato M; Nakamura H; Mizuno S; Shono F; Funatsu K; Yamazaki H
    Chem Res Toxicol; 2019 Jan; 32(1):211-218. PubMed ID: 30511563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of Minimal Physiologically Based Pharmacokinetic Models for Assessing Fractional Distribution, Oral Absorption, and Series-Compartment Models of Hepatic Clearance.
    Li X; Jusko WJ
    Drug Metab Dispos; 2023 Oct; 51(10):1403-1418. PubMed ID: 37460222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A physiologically based pharmacokinetic model for valnemulin in rats and extrapolation to pigs.
    Yuan LG; Luo XY; Zhu LX; Wang R; Liu YH
    J Vet Pharmacol Ther; 2011 Jun; 34(3):224-31. PubMed ID: 20950354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition.
    Poulin P; Theil FP
    J Pharm Sci; 2002 May; 91(5):1358-70. PubMed ID: 11977112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of Preclinical Pharmacokinetic Properties and Prediction of Human PK Using a Physiologically Based Pharmacokinetic Model for a Novel Anti-Arrhythmic Agent Sulcardine Sulfate.
    Ren C; Wang Y; Zhang M; Kong D; Ning C; Cheng Y; Bian Y; Sun M; Su S; Wang Y; Zhang Y; Lu Y; Li N; Zhao D; Chen X
    Pharm Res; 2021 Nov; 38(11):1847-1862. PubMed ID: 34773182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving non-linear tissue uptake.
    Laplanche R; Meno-Tetang GM; Kawai R
    J Pharmacokinet Pharmacodyn; 2007 Jun; 34(3):373-400. PubMed ID: 17431753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Accurately Predicts the Better Bronchodilatory Effect of Inhaled Versus Oral Salbutamol Dosage Forms.
    Boger E; Fridén M
    J Aerosol Med Pulm Drug Deliv; 2019 Feb; 32(1):1-12. PubMed ID: 29878860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of Human Distribution Volumes of Compounds in Various Elimination Phases Using Physiologically Based Pharmacokinetic Modeling and Experimental Pharmacokinetics in Animals.
    Shimizu H; Yoshida K; Nakada T; Kojima K; Ogasawara A; Nakamaru Y; Yamazaki H
    Drug Metab Dispos; 2019 Feb; 47(2):114-123. PubMed ID: 30420404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of miltefosine as an oral treatment for leishmaniasis.
    Sindermann H; Engel J
    Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S17-20. PubMed ID: 16730362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigating the Role of Altered Systemic Albumin Concentration on the Disposition of Theophylline in Adult and Pediatric Patients with Asthma by Using the Physiologically Based Pharmacokinetic Approach.
    Rasool MF; Khalid R; Imran I; Majeed A; Saeed H; Alasmari F; Alanazi MM; Alqahtani F
    Drug Metab Dispos; 2020 Jul; 48(7):570-579. PubMed ID: 32393652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Miltefosine Lipid Nanocapsules for Single Dose Oral Treatment of Schistosomiasis Mansoni: A Preclinical Study.
    Eissa MM; El-Moslemany RM; Ramadan AA; Amer EI; El-Azzouni MZ; El-Khordagui LK
    PLoS One; 2015; 10(11):e0141788. PubMed ID: 26574746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and Verification of a Linked
    Patilea-Vrana GI; Unadkat JD
    Drug Metab Dispos; 2021 Jul; 49(7):509-520. PubMed ID: 33952608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.